Seroconversion in Patients With Rheumatic Diseases Treated With Immunomodulators or Immunosuppressants, Who Were Inadvertently Revaccinated Against Yellow Fever

Oliveira, Ana; Mota, Lícia Maria Henrique da; Santos-Neto, Leopoldo Luiz dos; Simões, Marisol; Martins‐Filho, Olindo Assis; Tauil, Pedro Luíz

doi:10.1002/art.38960

Cited by 38 publications

(26 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In total, 27 out of 31 (87%) presented protective titers of neutralizing antibodies. The lowest PRNT value was in a patient who had used rituximab prior to the booster [45].…”

Section: Studies Selected and Data Extractedmentioning

confidence: 94%

“…The participants were subjects who had received the YFV despite a diagnosis of CIMID and no SAE was reported. There was no difference in AEFV occurrence between patients and healthy individuals [35,[41][42][43][44][45][46][47][48].…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

“…Five observational studies [41,42,44,45,48] evaluated the neutralizing antibodies to YFV in 180 patients with CIMID using immunosuppressant drugs, including corticosteroids, synthetic or biological. The authors concluded that all immunocompromised patients were able to develop a protective response to the yellow fever booster.…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

“…The quality of evidence was very poor. Oliveira et al (2015) analyzed the presence of neutralizing antibodies in 31 patients diagnosed with rheumatic diseases who had been inadvertently vaccinated with a booster of YFV (without the physician's knowledge) [45] during a YF outbreak (2007)(2008). Twenty-three subjects with RA, five with SLE, two with ES, and one with ankylosing spondylitis were included in the study.…”

Section: Studies Selected and Data Extractedmentioning

confidence: 99%

“…Recently, Valim et al (2017), enrolled 241 patients with rheumatic diseases for whom no SAE was reported, s described above [46]. Additionally, case reports of patients with CIMID using synthetic or biological DMARDs were described without any reported of SAE [33,35,41,42,44,45,49,[63][64][65][66][67].…”

Section: Sae In Altered Immune Status Patientsmentioning

confidence: 99%

See 4 more Smart Citations

Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases

et al. 2019

View full text Add to dashboard Cite

Background: In Brazil, we are facing an alarming epidemic scenario of Yellow fever (YF), which is reaching the most populous areas of the country in unvaccinated people. Vaccination is the only effective tool to prevent YF. In special situations, such as patients with chronic immune-mediated inflammatory diseases (CIMID), undergoing immunosuppressive therapy, as a higher risk of severe adverse events may occur, assessment of the risk-benefit ratio of the yellow fever vaccine (YFV) should be performed on an individual level. Main body of the abstract: Faced with the scarcity of specific orientation on YFV for this special group of patients, the Brazilian Rheumatology Society (BRS) endorsed a project aiming the development of individualized YFV recommendations for patients with CIMID, guided by questions addressed by both medical professionals and patients, followed an internationally validated methodology (GIN-McMaster Guideline Development). Firstly, a systematic review was carried out and an expert panel formed to take part of the decision process, comprising BRS clinical practitioners, as well as individuals from the Brazilian Dermatology Society (BDS), Brazilian Inflammatory Bowel Diseases Study Group (GEDIIB), and specialists on infectious diseases and vaccination (from Tropical Medicine, Infectious Diseases and Immunizations National Societies); in addition, two representatives of patient groups were included as members of the panel. When the quality of the evidence was low or there was a lack of evidence to determine the recommendations, the decisions were based on the expert opinion panel and a Delphi approach was performed. A recommendation was accepted upon achieving ≥80% agreement among the panel, including the patient representatives. As a result, eight recommendations were developed regarding the (Continued on next page)

show abstract

“…In total, 27 out of 31 (87%) presented protective titers of neutralizing antibodies. The lowest PRNT value was in a patient who had used rituximab prior to the booster [45].…”

Section: Studies Selected and Data Extractedmentioning

confidence: 94%